Al. Pecora et al., CD34(-) CELLS INFLUENCE DAYS TO ENGRAFTMENT AND TRANSFUSION REQUIREMENTS IN AUTOLOGOUS BLOOD STEM-CELL RECIPIENTS()CD33(), Journal of clinical oncology, 16(6), 1998, pp. 2093-2104
Purpose: To evaluate the reliability of CD34/CD33 subset enumeration a
s a predictor of hematopoietic repopulating potential in autologous bl
ood stem-cell transplantation and to determine which patient and treat
ment-related factors affect the timing, quantity and type of blood ste
m cells mobilized. Patients and Methods: We analyzed blood stem-cell c
ollections from 410 consecutive cancer patients who received mobilizat
ion therapy and evaluated factors, including CD34(+) subset quantities
, that might influence engraftment kinetics and transfusion requiremen
ts in autologous blood stem-cell recipients. Results: The majority of
patients (97%) mobilized CD34(+)33(-) cells, which were usually collec
ted in the greatest quantity on the first day of apheresis. Patients w
ho received only growth factor mobilized the highest percentage of CD3
4(+)33(-) cells. Extensive prior chemotherapy limited the collection o
f CD34(+)33(-) cells. In addition to patient diagnosis (P < .006) and
total CD34(+) cell dose (P = .0001), CD34(+)33(-) cell dose (P < .005)
and percentage of CD34(+)33(-) cells (P < .005) were identified as in
dependent factors significantly predictive of engraftment kinetics. CD
34(+)33(-) cell dose(R-2 less than or equal to .177; P < .0001)was a s
trong and the only significant predictor of RBC and platelet transfusi
on requirements. Furthermore, independent of the total CD34(+) cell do
se, as the CD34(+)33(-) cell dose increased, days to neutrophil recove
ry, days to platelet recovery, and transfusion requirements decreased.
Conclusion: These findings show that CD34(+)33(-) cells are readily c
ollected in most cancer patients and significantly influence engraftme
nt kinetics and transfusion requirements in autologous blood stem-cell
recipients. CD34(+)33(-) cell quantity of the blood stem-cell graft a
ppears to be a more reliable predictor of hematopoietic recovery rates
than total CD34(+) cell quantity in this setting.